Dechow T, Aldaoud A, Behlendorf T, et al. - Pomalidomide plus low-dose dexamethasone (POM/DEX) is a safe and effective treatment option for relapsed or refractory multiple myeloma (R/RMM) patients pretreated with lenalidomide and bortezomib. Also, the POM/DEX regimen is clinically valuable in the real-world setting.

• A prospective non-interventional study (POSEIDON) including patients with R/RMM pretreated with at least two prior therapy lines including both lenalidomide and bortezomib in the real world in Germany.

• Patients were treated with POM/DEX according to physicians’ choice.

• Of 151 enrolled patients, 144 with a median of three prior therapy lines were eligible for effectiveness analysis (median age was 73.2 years).

• The observed median progression-free and overall survival were 6.3 months and 12.9 months, respectively.

• Leukopenia (8.2%), pneumonia (7.5%) and anemia (5.5%) were documented as the most frequent grade 3/4 adverse events.

• Post-initiation of POM/DEX, quality of life was maintained.